Lidamycin decreases CD133 expression in hepatocellular carcinoma via the Notch signaling pathway

  • Authors:
    • Yi Chen
    • Wenwei Sun
    • Ran He
    • Feiyan Zhang
    • Hongyu Wang
    • Panhong Li
    • Rong‑Guang Shao
    • Xiaoyu Xu
  • View Affiliations

  • Published online on: October 20, 2017     https://doi.org/10.3892/ol.2017.7248
  • Pages:7889-7895
0

Abstract

Cluster of differentiation (CD)133 is considered a molecular marker of cancer stem cells in hepatocellular carcinoma. In the present study, the effect of lidamycin (LDM) on CD133 expression in hepatocellular carcinoma (Huh7 cells) was evaluated and the potential molecular mechanism was investigated. Flow cytometry analysis, as well as sorting, sphere formation and western‑blot assays, were performed in vitro to explore the effects of LDM on CD133 expression. A subcutaneous tumor model in nude mice was used to observe the effects of LDM on tumor volume and CD133 protein in vivo. To investigate the potential underlying molecular mechanism, Notch signaling pathway activity was detected by western blot analysis and reverse transcription‑quantitative polymerase chain reaction. The proportion of CD133+ cells and the expression of CD133 protein were revealed to be downregulated by LDM. Sphere formation of sorted CD133+ cells was suppressed 7 days after LDM treatment. In addition, LDM inhibited tumor volume formed from sorted CD133+ cells and CD133 protein level in vivo. LDM decreased the mRNA level of NOTCH1, Hes1 (Hes family BHLH transcription factor 1) and Hey1 (Hes‑related family BHLH transcription factor with YRPW motif 1) genes; consequently, the protein expression of NOTCH1, Notch intracellular domain, Hes1 and Hey1 was decreased by LDM. Downregulation of the Notch signaling pathway by LDM was enhanced through combination with N‑[N‑(3,5‑difluorophenacetyl)‑L‑alanyl]‑S‑phenylglycine t‑butyl ester. In brief, these data suggest that LDM suppresses CD133 expression via the Notch signaling pathway, indicating the potential mechanism of LDM on CD133 and the benefits for further clinical application.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, Y., Sun, W., He, R., Zhang, F., Wang, H., Li, P. ... Xu, X. (2017). Lidamycin decreases CD133 expression in hepatocellular carcinoma via the Notch signaling pathway. Oncology Letters, 14, 7889-7895. https://doi.org/10.3892/ol.2017.7248
MLA
Chen, Y., Sun, W., He, R., Zhang, F., Wang, H., Li, P., Shao, R., Xu, X."Lidamycin decreases CD133 expression in hepatocellular carcinoma via the Notch signaling pathway". Oncology Letters 14.6 (2017): 7889-7895.
Chicago
Chen, Y., Sun, W., He, R., Zhang, F., Wang, H., Li, P., Shao, R., Xu, X."Lidamycin decreases CD133 expression in hepatocellular carcinoma via the Notch signaling pathway". Oncology Letters 14, no. 6 (2017): 7889-7895. https://doi.org/10.3892/ol.2017.7248